From Junior Mints to robotics, the state already produces more than you think - but the next economic development chief needs ...

SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

Governance lapses, inconsistent communication, and a disconnect between leadership decisions and societal realities have eroded confidence. Today’s leaders must move beyond compliance and embrace ...

HYDERABAD: A high-level Indo-French business roundtable was held at the Secretariat on Tuesday, bringing together senior state government officials and a delega ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s ...

How TIME and Statista Determined the World's Most Sustainable Companies of 2025 In the fight against climate change, ...

Results presented at the 85th Scientific Sessions of the American Diabetes Association in Chicago highlight the potential for ...

Rezpegaldesleukin, an IL-pathway agonist and regulatory T-cell (Treg) proliferator, was being investigated in the REZOLVE-AD ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...